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We assessed the influence that consecutive-day blood sam-
pling, compared with single-day blood sampling, had on
polymerase chain reaction (PCR)–adjusted parasitological
cure after stepwise genotyping of merozoite surface proteins
2 (msp2) and 1 (msp1) in 106 children in Tanzania who had
uncomplicated falciparum malaria treated with either sul-
fadoxine-pyrimethamine or artemether-lumefantrine; 78 of
these children developed recurrent parasitemia during the
42-day follow-up period. Initial msp2 genotyping identified
27 and 33 recrudescences by use of single- and consecutive-
day sampling, respectively; in subsequent msp1 genotyping,
17 and 21 of these episodes, respectively, were still classified
as recrudescences; these results indicate a similar sensitivity
of the standard single-day PCR protocol—that is, 82% (27/
33) and 81% (17/21), in both genotyping steps. Interpreta-
tion of PCR-adjusted results will significantly depend on
methodology.
To ensure effective and life-saving treatment for sick children,
accurate results from efficacy trials are essential for adequate
policy decisions on the use of antimalarial drugs in Africa. The
World Health Organization (WHO) recommends that a new
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antimalarial treatment should have an average cure rate of
95%, as assessed in clinical trials, and that a review-/change-
of-treatment policy should be initiated when the efficacy of a
recommended treatment falls to !90% [1].
The recent introduction of genotyping of Plasmodium fal-
ciparum by polymerase chain reaction (PCR), as a tool to dis-
tinguish between treatment failure (recrudescence) and new
infection (reinfection), has significantly improved the assess-
ment of parasitological cure rates, particularly in antimalarial-
drug trials conducted in high-transmission areas with extended
follow-up beyond day 14. However, because of inherent limi-
tations of the PCR technique and constraints imposed by the
biology of the parasite [2], PCR-adjusted outcomes should be
interpreted with caution.
PCR adjustment to differentiate between recrudescence and
reinfection is presently achieved by analysis of one or a com-
bination of highly polymorphic genetic markers—for example,
merozoite surface proteins 1 (msp1) and 2 (msp2)—from paired
blood samples collected at the day of enrollment and the day
of recurrent parasitemia. However, the use of PCR analysis of
such paired blood samples in antimalarial-drug trials will not
reflect the daily dynamics of P. falciparum populations previ-
ously shown in asymptomatic children in high-transmission
areas [3]. This observation may also have implications for
symptomatic P. falciparum infections and needs to be consid-
ered in clinical-trial protocols, to establish PCR-adjusted par-
asitological cure. In previous studies of parasite population
dynamics during the early phase of treatment of travelers re-
turning with symptomatic malarial infection, Fa¨rnert et al.
found a consistent genotype pattern during consecutive-day
sampling [4], whereas Jafari et al., using a novel quantitative
method, detected different genotypes at different time points
[5]. In Gabonese children treated with quinine, the same ge-
notype pattern was observed during the infection, although
alleles disappeared and reappeared over time in some children
[6]. However, none of these studies applied consecutive-day
sampling during recurrent parasitemia.
We report here data from a clinical trial of uncomplicated
childhood P. falciparum malaria, a trial that was conducted in
a high-transmission area in Tanzania and that had the primary
objective of assessing the influence that consecutive-day blood
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sampling had on PCR-adjusted parasitological cure rates (PCR-
APCRs), compared with a standard protocol using paired blood
samples only. This scientific question was recently identified,
by WHO, as a research priority [7].
Methods. The study was conducted during April–July 2004
in Fukayosi, Bagamoyo District, Tanzania, which is located in
a rural area with holoendemic malaria transmission. The trial
was conducted in accordance with the Declaration of Helsinki
and was approved by the ethics committees at the Muhimbili
University College of Health Sciences (Tanzania) and the Ka-
rolinska Institutet (Sweden). Informed consent was obtained
from the parents/guardians of all children enrolled in the study.
Inclusion criteria included a blood sample positive for P. fal-
ciparum at a density of 2000–200,000 asexual parasites/mL of
blood, age 6 months, body weight 6 kg, and either axillary
temperature37.5C or a history of fever during the preceding
24 h; exclusion criteria included symptoms/signs of severe ma-
laria, hemoglobin level !50g/L, and any serious underlying dis-
ease or known allergy to study drugs.
Enrolled children were assigned randomly to receive a fixed
combination of either (1) sulfadoxine-pyrimethamine (Fan-
sidar; Roche) as a single dose under supervision or (2) arte-
mether-lumefantrine (Coartem; Novartis), twice daily and on
the basis of body weight, for 3 days. For logistic reasons, only
the first of the 2 daily doses of artemether-lumefantrine were
administered under supervision.
The duration of outpatient follow-up of the children was 42
days. Clinical and laboratory assessments were conducted on
days 0, 1, 2, 3, 7, 14, 21, 28, 35, and 42 or on any day of re-
current illness.
Giemsa-stained thick-blood films were examined, quantified
(in terms of parasites per microliter), and recorded at each
clinic visit. Quality control was performed according to WHO
recommendations [7].
PCR-APCRs were analyzed by use of stepwise genotyping,
as described by Mugittu et al. [8]. Initially, all blood samples
collected at enrollment and during recurrent parasitemia were
analyzed by use of the msp2 marker, for both assessment of
parasite-population complexity and establishment of PCR-ad-
justed cure. In a second step, performed by use of another
highly polymorphic genetic marker, all children with recurrent
parasitemia underwent additional genotyping, using the msp1
marker, to confirm the presence of recrudescences and to assess
the distribution of PCR outcome.
All genotyping was performed from dried blood spots on
filter paper (3MM; Whatman), on the basis of previously de-
scribed nested-PCR protocols [9]. PCR results for paired blood
samples collected on the day of enrollment and the day of
recurrent parasitemia (standard protocol) were compared, as
were those for paired blood samples collected on 4 consecutive
days after enrollment and on 2 consecutive days of recurrent
parasitemia (enhanced protocol). For each child, all samples
were amplified in the same PCR run. The PCR products were
loaded in parallel on the same gel and were separated by elec-
trophoresis, for analysis of both the number of genotypes and
size polymorphism.
For each step and protocol, recrudescence was defined as the
presence of at least 1 matching allelic band, and reinfection
was defined as the absence of any matching allelic band in
samples collected at enrollment and during recurrent parasi-
temia. Children with PCR results that, on the basis of either
the msp2 or msp1 genotyping, fulfilled the reinfection criteria
were considered to be treatment successes; children with neg-
ative PCR amplification at enrollment and/or during recurrent
parasitemia were considered to have nonconclusive PCR out-
comes. The primary objective was to evaluate the different
sampling protocols, and the study was considered to be ex-
ploratory. A sample of 100 children, with a minimum of 50 in
each treatment arm, was predefined. Data were entered, vali-
dated, and analyzed by use of SPSS (version 14.0) software.
Proportions were compared by x2 test, Fisher’s exact test,
and relative risk (RR), as appropriate. Continuous variables
were compared by paired-sample t test. Statistical significance
was defined as . The intention-to-treat approach wasP .05
used to analyze the primary efficacy outcome in all children
enrolled. Children lost to follow-up who did not have a defined
primary efficacy outcome were kept in the analyses until their
day of exit, after which they no longer contributed to the de-
nominator in the calculations performed.
Results. A total of 434 children were screened for eligibil-
ity. Of the 175 (40%) who had a blood-slide sample positive
for P. falciparum, 69 were excluded (61 had a parasite density
!2000/mL, 4 had severe malaria, 2 lived outside the study area,
1 left the clinic without notice, and 1 had a severe concomitant
disease); the remaining 106 children were enrolled, and 56 of
them were randomly assigned to treatment with sulfadoxine-
pyrimethamine, 50 to treatment with artemether-lumefantrine.
Baseline clinical and demographic data showed no significant
differences between the 2 treatments: in both groups, the geo-
metric mean parasite count at enrollment was ∼21,600/mL, and
no deaths occurred. Because 3 of the 56 children treated with
sulfadoxine-pyrimethamine traveled outside the study area and
were lost to follow-up (1 each on days 28, 35, and 42 after
treatment), a total of 103 (97%) of the 106 enrolled children
were available for analysis of primary efficacy outcome by day
42 after treatment.
PCR-based msp2 genotyping of blood samples collected on
days 1–3 identified 32 additional (i.e., compared with those
seen at day 0) parasite genotypes in 26 (25%) of the 106 enrolled
children; of these additional genotypes, 21, 8, and 3 were de-
tected on days 1, 2, and 3, respectively. When these additional
32 genotypes were included as part of the initial infection, the
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Figure 1. Flow chart of outcome of polymerase chain reaction (PCR), using stepwise genotyping consisting of initial msp2 genotyping followed by msp1
genotyping, for the single-day– and consecutive-day–sampling protocols.
proportion of children with multiple genotypes increased from
60/106 (57%) to 73/106 (69%), although there was no effect
on the number of genotypes detected (median, 2 [range, 0–
7]). Similarly, in 10/78 (13%) children with recurrent parasi-
temia, a total of 11 parasite genotypes were detected not on
the initial day but on the following day. When these 11 ge-
notypes were included as part of the recurrent parasitemia, the
proportion of children with multiple genotypes increased from
45/78 (58%) to 48/78 (62%), although there was no effect on
the number of genotypes detected (median, 2 [range, 0–5]).
The PCR outcome for the entire cohort, as established by
stepwise genotyping of msp2 and msp1 for the 2 sampling pro-
tocols, is presented in figure 1. Of the 33 recrudescences iden-
tified by the initial msp2 analysis, 6 (18%) were identified
exclusively by the enhanced protocol with consecutive-day sam-
pling, meaning that the sensitivity of the standard protocol was
27/33 (82% [95% confidence interval {CI}, 68%–96%]). When
PCR results from days 3 and 4 after enrollment were considered,
only 1 of the 6 additional recrudescences identified exclusively
by the enhanced protocol was detected.
After the additional msp1 analysis, 21 episodes were still clas-
sified as recrudescences (treatment failures); 4 (19%) of these
21 were so classified on the basis of the enhanced protocol, all
4 by combining PCR results from the first 2 consecutive days
after enrollment and from 2 days of recurrent parasitemia; the
sensitivity of the standard protocol in the second genotyping
step was therefore 17/21 (81% [95% CI, 63%–99%]).
When msp1 was used as the initial marker for genotyping,
the distribution of PCR results in all 78 children with recurrent
parasitemia was similar to that when msp2 was used as the
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Table 1. Crude and polymerase chain reaction (PCR)–adjusted cure rates, and relative risk (RR) for the asso-
ciation between treatment type and cure rate, both after initial msp2 genotyping and after additional msp1
genotyping.
Day, protocola
Cure rate, proportion (%)
Relative risk,
SP vs. ALEntire cohort (n p 106)
Treatment
with SP (n p 50)
Treatment
with AL (n p 56)
Initial msp2 genotyping
14
PCR unadjusted 97/106 (92) 48/56 (86) 49/50 (98) 1.80 (1.32–2.44)
PCR-APCR
Standard 98/106 (92) 49/56 (88) 49/50 (98) 1.75 (1.26–2.43)
Enhanced 97/106 (92) 48/56 (86) 49/50 (98) 1.80 (1.32–2.44)
28
PCR unadjusted 48/105 (46) 24/55 (44) 24/50 (48) 1.09 (0.75–1.57)
PCR-APCR
Standard 83/105 (79) 39/55 (71) 44/50 (88) 1.55 (1.10–2.18)
Enhanced 78/105 (74) 36/55 (66) 42/50 (84) 1.52 (1.08–2.15)
42
PCR unadjusted 25/103 (24) 13/53 (24) 12/50 (24) 0.99 (0.64–1.52)
PCR-APCR
Standard 76/103 (74) 33/53 (62) 43/50 (86) 1.71 (1.21–2.40)
Enhanced 70/103 (68) 29/53 (55) 41/50 (82) 1.76 (1.24–2.49)
Additional msp1 genotyping of recrudescences defined by msp2 genotyping (n p 33)
14
PCR-APCR
Standard 99/106 (93) 49/56 (88) 50/50 (100) 2.02 (1.66–2.46)
Enhanced 98/106 (92) 49/56 (88) 49/50 (98) 1.75 (1.26–2.43)
28
PCR-APCR
Standard 90/105 (86) 41/55 (74) 49/50 (98) 2.05 (1.58–2.67)
Enhanced 87/105 (83) 40/55 (73) 47/50 (94) 1.81 (1.33–2.46)
42
PCR-APCR
Standard 86/103 (84) 37/53 (70) 49/50 (98) 2.19 (1.67–2.87)
Enhanced 82/103 (80) 35/53 (66) 47/50 (94) 2.01 (1.48–2.73)
NOTE. AL, artemether-lumefantrine; PCR-APCR, PCR-adjusted parasitological cure rate; SP, sulfadoxine-pyrimethamine.
a In the standard protocol, PCR adjustment was performed with paired blood samples collected on the day of enrollment and the
day of recurrent parasitemia; in the enhanced protocol, PCR adjustment was performed with paired blood samples collected on 4
consecutive days after enrollment and on 2 consecutive days of recurrent parasitemia.
initial marker: for the paired and consecutive-day samples, re-
spectively, 26 and 32 episodes were defined as recrudescences,
46 and 44 as reinfections, and 6 and 2 as nonconclusive PCR
outcomes. When the 6 episodes initially defined as noncon-
clusive by the paired-samples protocol were analyzed by the
enhanced protocol, 3 were classified as recrudescences, 1 as a
reinfection, and 2 as nonconclusive.
For the entire cohort, the crude cure rates and PCR-APCRs
by days 14, 28, and 42 of follow-up, as well as the respective
analyses using the 2 different genotyping steps and sampling
protocols, are presented in table 1.
Discussion. The results of this clinical trial of uncompli-
cated childhood malaria, conducted during a highly intensive
transmission period in Bagamoyo District, Tanzania, indicate
that a single blood sample may not provide a complete picture
of all parasite subpopulations present in an individual. The
similar proportion of recrudescences that were identified ex-
clusively by consecutive-day (4+2 days) sampling but were de-
fined as either reinfections or nonconclusive PCR results when
the standard single-day (1+1 day) protocol was used in both
genotyping steps suggests that PCR protocols using paired
blood samples may overestimate the efficacy that antimalarial
drugs have in high-transmission areas.
The additional genotypes identified by consecutive-day sam-
pling but not detectable at the day of enrollment (i.e., not
detectable by single-day sampling) could be a reflection of either
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the parasite population dynamics of P. falciparum [3] or the
PCR technique’s limitations, which are due to template com-
petition in complex infections, in detecting all minority ge-
notypes that are present [2].
The handling and interpretation of nonconclusive PCR re-
sults is a dilemma in antimalarial-drug trials, because such
results can represent either recrudescences or reinfections.
Thus, an advantage of the enhanced protocol used in the pres-
ent study was the improved ability to retrieve PCR-adjusted
outcomes in children for whom paired blood samples showed
nonconclusive PCR results.
In the present study, we have used stepwise genotyping of
2 highly polymorphic loci to distinguish between treatment
failure and new infection, an approach recently proposed by
Mugittu et al. [8]. Interestingly, the distribution of PCR-ad-
justed outcomes was similar when the initial marker used for
genotyping was either msp2 or msp1. However, when the 2
markers were combined, the PCR-adjusted outcome changed
significantly, with a substantial number of recrudescences being
reclassified as reinfections. This finding is consistent with the
results reported by Mugittu et al. [8] and indicates that the use
of a single genetic marker to establish the PCR-adjusted cure
may result in an underestimation of drug efficacy. On the other
hand, the increased specificity achieved with incorporation of
multiple genetic markers into the PCR analysis will simulta-
neously reduce the sensitivity of detection of true recrudes-
cences arising from minority clones, which may not be detected
by all markers, a result that may, instead, underestimate treat-
ment failure.
Because a majority of both of the additional genotypes used
in the present study were detected on the first day after en-
rollment, and because the additional recrudescences were iden-
tified by combining PCR results from 2 consecutive days both
at enrollment and during recurrent parasitemia, we suggest that
this sampling model (2+2 days) should be the primary target
for future studies assessing the efficiency of consecutive-day
sampling in different endemic settings in Africa.
In conclusion, the range of possible PCR-APCRs for the
entire cohort varied from 86% by day 28, when stepwise ge-
notyping with msp2 and msp1 and the standard paired-samples
protocol were used, to 68% during an extended follow-up to
day 42, when a single genetic marker (msp2) and the enhanced
protocol were used. These results underscore how sensitive the
assessment of PCR-adjusted cure is to the choice of method-
ology, and this has critical implications in the interpretation of
data from in vivo studies, particularly in the context of evi-
dence-based decisions on new antimalarial-drug policies in
Africa.
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